These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

729 related items for PubMed ID: 16204009

  • 1. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S.
    J Clin Oncol; 2005 Dec 10; 23(35):8942-9. PubMed ID: 16204009
    [Abstract] [Full Text] [Related]

  • 2. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN, Tang AZ, Zhou L, Huang GW, Wang Z, Zeng Y.
    Chin Med J (Engl); 2009 May 20; 122(10):1173-8. PubMed ID: 19493466
    [Abstract] [Full Text] [Related]

  • 3. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, Ueda Y.
    Oncol Rep; 2004 Oct 20; 12(4):725-31. PubMed ID: 15375491
    [Abstract] [Full Text] [Related]

  • 4. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP.
    Cancer Res; 2001 Aug 15; 61(16):6219-26. PubMed ID: 11507075
    [Abstract] [Full Text] [Related]

  • 5. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells].
    Chen LP, Huang JQ, Zhou TC, Zhang SX, Wang JL.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug 15; 28(8):1431-3. PubMed ID: 18753079
    [Abstract] [Full Text] [Related]

  • 6. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.
    Xu JJ, Yao K, Yu CJ, Chen X, Lu MP, Sun H, Li BZ, Ding CN, Zhou F.
    Auris Nasus Larynx; 2006 Dec 15; 33(4):441-6. PubMed ID: 16934422
    [Abstract] [Full Text] [Related]

  • 7. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
    Whitney BM, Chan AT, Rickinson AB, Lee SP, Lin CK, Johnson PJ.
    J Med Virol; 2002 Jul 15; 67(3):359-63. PubMed ID: 12116028
    [Abstract] [Full Text] [Related]

  • 8. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
    Comoli P, De Palma R, Siena S, Nocera A, Basso S, Del Galdo F, Schiavo R, Carminati O, Tagliamacco A, Abbate GF, Locatelli F, Maccario R, Pedrazzoli P.
    Ann Oncol; 2004 Jan 15; 15(1):113-7. PubMed ID: 14679129
    [Abstract] [Full Text] [Related]

  • 9. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
    Nolte A, Buhmann R, Straka C, Emmerich B, Hallek M.
    Bone Marrow Transplant; 1998 May 15; 21(9):909-16. PubMed ID: 9613783
    [Abstract] [Full Text] [Related]

  • 10. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
    Dolcetti R, Frisan T, Sjöberg J, De Campos-Lima PO, Pisa P, De Re V, Gloghini A, Rizzo S, Masucci MG, Boiocchi M.
    Cancer Res; 1995 Aug 15; 55(16):3675-81. PubMed ID: 7627978
    [Abstract] [Full Text] [Related]

  • 11. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
    Karlsson H, Brewin J, Kinnon C, Veys P, Amrolia PJ.
    J Immunother; 2007 Aug 15; 30(5):544-56. PubMed ID: 17589295
    [Abstract] [Full Text] [Related]

  • 12. Combined transfection with EBV-specific epitopes and HLA-A2 genes is more effective than separate transfection in promoting CTL lysis against nasopharyngeal carcinoma.
    Ding W, Fong C.
    Cell Mol Immunol; 2004 Jun 15; 1(3):229-34. PubMed ID: 16219173
    [Abstract] [Full Text] [Related]

  • 13. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB.
    J Immunol; 1997 Apr 01; 158(7):3325-34. PubMed ID: 9120290
    [Abstract] [Full Text] [Related]

  • 14. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH, Brestrich G, Mittenzweig A, Roemhild A, Zwinger S, Subklewe M, Beier C, Kurtz A, Babel N, Volk HD, Reinke P.
    J Immunother; 2007 Apr 01; 30(8):817-24. PubMed ID: 18049333
    [Abstract] [Full Text] [Related]

  • 15. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.
    Cancer; 2004 Mar 15; 100(6):1162-70. PubMed ID: 15022282
    [Abstract] [Full Text] [Related]

  • 16. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
    Meij P, Bloemena E, Palmen N, Brink A, Vervoort MB, Meijer CJ, Middeldorp JM.
    Cell Immunol; 2001 Feb 25; 208(1):25-33. PubMed ID: 11277616
    [Abstract] [Full Text] [Related]

  • 17. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma.
    Wheatley GH, McKinnon KP, Iacobucci M, Mahon S, Gelber C, Lyerly HK.
    Surgery; 1998 Aug 25; 124(2):171-6. PubMed ID: 9706135
    [Abstract] [Full Text] [Related]

  • 18. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
    Subklewe M, Sebelin K, Block A, Meier A, Roukens A, Paludan C, Fonteneau JF, Steinman RM, Münz C.
    Hum Immunol; 2005 Sep 25; 66(9):938-49. PubMed ID: 16360833
    [Abstract] [Full Text] [Related]

  • 19. Immunotherapy for Hodgkin's disease.
    Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, Wagner HJ, Anderson R, Prentice HG, Brenner MK, Heslop HE.
    Ann Hematol; 2002 Sep 25; 81 Suppl 2():S39-42. PubMed ID: 12611071
    [Abstract] [Full Text] [Related]

  • 20. [Recombinant AAV-LMP-induced LMP specific cytotoxic response to autologous lymphoblastoid cell lines tranformed by Epstein-Barr virus].
    Zhao F, Liu H, Zhou L, Cai W, Du B, Ye S, Zeng Y.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep 25; 11(3):247-51. PubMed ID: 15617340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.